These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34844627)

  • 1. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy.
    Peng X; Zhang S; Jiao W; Zhong Z; Yang Y; Claret FX; Elkabets M; Wang F; Wang R; Zhong Y; Chen ZS; Kong D
    J Exp Clin Cancer Res; 2021 Nov; 40(1):374. PubMed ID: 34844627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
    Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
    Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
    Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
    Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
    Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
    Zhang S; Peng X; Li X; Liu H; Zhao B; Elkabets M; Liu Y; Wang W; Wang R; Zhong Y; Kong D
    Cell Death Dis; 2021 May; 12(6):546. PubMed ID: 34039959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
    Shiri Heris R; Safaroghli-Azar A; Yousefi AM; Hamidpour M; Bashash D
    Cell Biol Int; 2020 May; 44(5):1212-1223. PubMed ID: 32068318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
    Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
    Brachmann SM; Kleylein-Sohn J; Gaulis S; Kauffmann A; Blommers MJ; Kazic-Legueux M; Laborde L; Hattenberger M; Stauffer F; Vaxelaire J; Romanet V; Henry C; Murakami M; Guthy DA; Sterker D; Bergling S; Wilson C; Brümmendorf T; Fritsch C; Garcia-Echeverria C; Sellers WR; Hofmann F; Maira SM
    Mol Cancer Ther; 2012 Aug; 11(8):1747-57. PubMed ID: 22653967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer.
    Van Eaton KM; Gustafson DL
    J Pharmacol Exp Ther; 2021 Dec; 379(3):331-342. PubMed ID: 34503992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
    Liu WL; Gao M; Tzen KY; Tsai CL; Hsu FM; Cheng AL; Cheng JC
    Oncotarget; 2014 Jun; 5(11):3662-72. PubMed ID: 25004403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
    Rosich L; Saborit-Villarroya I; López-Guerra M; Xargay-Torrent S; Montraveta A; Aymerich M; Villamor N; Campo E; Pérez-Galán P; Roué G; Colomer D
    Haematologica; 2013 Nov; 98(11):1739-47. PubMed ID: 23850807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
    Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
    Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
    Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
    Hu Y; Guo R; Wei J; Zhou Y; Ji W; Liu J; Zhi X; Zhang J
    Cell Death Dis; 2015 Dec; 6(12):e2020. PubMed ID: 26673665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.